Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.

BACKGROUND AND OBJECTIVES CD58, a member of the Ig superfamily, is expressed by hematopoietic and non- hematopoietic cells. It has been demonstrated to be over-expressed in precursor-B acute lymphoblastic leukemia (ALL) blasts when compared to in their normal counterparts, suggesting its potential use in the detection of minimal residual disease (MRD) by flow cytometry (FC). To assess the reliability and accuracy of CD58 for this purpose, we studied its expression in a large series of normal and ALL bone marrow (BM) samples using quantitative FC. DESIGN AND METHODS We studied 180 precursor-B ALL BM samples at diagnosis (8 pro-B, 164 early-B, 8 mature-B ALL) and 123 follow-up BM samples (n=54 at day +15 and n=69 at day +78), as well as 51 normal BM samples and 7 regenerating BM samples from patients with T-ALL at week 12. We used four-color quantitative FC, focusing analysis on CD58 expression. In follow-up samples from day +78, the MRD level was simultaneously evaluated by real time quantitative polymerase chain reaction (RQ-PCR) amplification of antigen receptor genes. RESULTS CD58 expression was significantly higher in ALL blasts than in normal B lymphocytes, while no significant differences between regenerating and normal B lymphocytes were observed. CD58 was expressed in 99.4% of the precursor-B ALL cases and 93.5% of these showed over-expression compared to normal. No significant modulation of CD58 expression during remission induction therapy was noted. Finally, 66 (95.6%) of 69 BM samples simultaneously analyzed using both FC and RQ-PCR at day +78 showed concordant results regarding MRD. INTERPRETATION AND CONCLUSIONS Our results confirm and further evidence the role of CD58 in the diagnosis and monitoring of precursor-B ALL. In particular, we demonstrated its stability and accuracy in MRD detection at clinically relevant time points. These findings indicate that CD58 is a powerful tool for MRD detection in precursor-B ALL.

[1]  Elaine Coustan-Smith,et al.  Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia , 1998, The Lancet.

[2]  W. Kamps,et al.  Regenerating normal B‐cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease , 2000, British journal of haematology.

[3]  M. Borowitz,et al.  Asynchronous Antigen Expression in B Lineage Acute Lymphoblastic Leukemia , 1988 .

[4]  P. Lacor,et al.  Different expression of adhesion molecules on CD34+ cells in AML and B‐lineage ALL and their normal bone marrow counterparts , 1999, European journal of haematology.

[5]  C. V. D. Schoot,et al.  Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia , 2000, Leukemia.

[6]  Michael N Dworzak,et al.  Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. , 2002, Blood.

[7]  D. Printz,et al.  Comparative phenotype mapping of normal vs. malignant pediatric B-lymphopoiesis unveils leukemia-associated aberrations. , 1998, Experimental hematology.

[8]  A. Órfão,et al.  Quantitative multiparametric immunophenotyping in acute lymphoblastic leukemia: correlation with specific genotype. I. ETV6/AML1 ALLs identification , 2000, Leukemia.

[9]  A Orfao,et al.  Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. Cavé,et al.  Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia , 1998 .

[11]  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998 .

[12]  J. Gabert,et al.  Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects , 2003, Leukemia.

[13]  A. Órfão,et al.  BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation. , 2001, Leukemia.

[14]  G. Janossy,et al.  Leukemia-associated changes identified by quantitative flow cytometry: I. CD10 expression. , 1994, Cytometry.

[15]  Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. , 2000 .

[16]  D. Campana,et al.  Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. , 2001, Blood.

[17]  H. Gralnick,et al.  The Morphological Classification of Acute Lymphoblastic Leukaemia: Concordance among Observers and Clinical Correlations , 1981, British journal of haematology.

[18]  M. Stul,et al.  Immunoglobulin and T cell receptor gene rearrangement patterns in acute lymphoblastic leukemia are less mature in adults than in children: implications for selection of PCR targets for detection of minimal residual disease , 1998, Leukemia.

[19]  F. Behm,et al.  Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. , 2002, Blood.

[20]  D. Campana,et al.  Detection of minimal residual disease in acute leukemia by flow cytometry. , 1999, Cytometry.

[21]  O. Haas,et al.  Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: a study of five cases controlled by genetic methods. , 1999, Experimental hematology.

[22]  Jennings Cd,et al.  Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy , 1997 .

[23]  L. Picker,et al.  Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. , 2001, Blood.

[24]  A Orfao,et al.  New methodologic approaches for immunophenotyping acute leukemias. , 2001, Haematologica.

[25]  H. Hooijkaas,et al.  Regeneration pattern of precursor-B-cells in bone marrow of acute lymphoblastic leukemia patients depends on the type of preceding chemotherapy , 2000, Leukemia.